Skip to main content

BB Biotech Value Stock - Dividend - Research Selection

BB Biotech AG

ISIN: CH0038389992, WKN: A0NFN3

Market price date: 21.05.2021
Market price: 78,45 CHF




BB Biotech AG Fundamental data and company key figures of the share

Annual reports in CHF
Key figures 27-04-2021
Cash flow
Net operating cash flow 262.450.000
Capital Expenditures -1
Free cash flow 213.778.000
Balance sheet
Total Equity 3.887.550.000
Liabilities & Shareholders equity 3.963.130.000
Income statement
Net income 691.174.000
Eps (diluted) 12,476
Diluted shares outstanding 55.400.000
Net sales/revenue 280.930.000

Fundamental ratios calculated on: 21-05-2021

Ratios
Key figures 21-05-2021
Cash flow
P/C 16,56
   
P/FC 20,33
Balance sheet
ROI17,44
ROE98,09
Income statement
P/E6,29
Div. Yield4,59%
P/B1,12
P/S15,47


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolBION.SW
Market Capitalization4.452.089.856,00 USD
Country
IndicesPrime All Share,SPI
Sectors
Raw Data SourceIFRS in Millionen CHF
Stock Split2016-03-29,5.000000/1.000000; 2001-05-18,10.0000/1.0000
Internetwww.bbbiotech.com


Description of the company

BB Biotech AG is a Switzerland-based investment company, which principal activity is to invest in companies active in the biotechnology industry. BB Biotech AG invests mainly in companies operating in such sectors as oncology, infectious diseases, cardiovascular diseases, metabolic diseases and autoimmune diseases. The Companys portfolio comprises between 20 and 35 companies and includes such companies as Celgene, Actelion, Vertex Pharmaceuticals, Gilead, Novo Nordisk, Incyte, Isis Pharmaceuticals, Immunogen, Halozyme Therapeutics, Ariad Pharmaceuticals, Biomarin Pharmaceutical, Alexion Pharmaceuticals, Optimer Pharmaceuticals, Achillion Pharmaceuticals, Swedish Orphan Biovitrum, Dendreon, Bavarian Nordic, Lupin, Glenmark Pharmaceuticals, Strides Arcolab, Endocyte, Probiodrug, and Idenix Pharmaceuticals.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.bbbiotech.com